Ruxolitinib phosphate
|
|
|
- CAS-Nr.
- 1092939-17-7
- Englisch Name:
- Ruxolitinib phosphate
- Synonyma:
- INC424;INCB 018424;INC 424 phosphate;Ruxotinib phosphate;Jakafi (ruxolitinib);IINCB018424 phosphate;Ruxolitinib, Phosphate;INCB018424 (phosphate);10-dimethoxyptercarpan;INCB 018424 (phosphate)
- CBNumber:
- CB82509943
- Summenformel:
- C17H21N6O4P
- Molgewicht:
- 404.37
- MOL-Datei:
- 1092939-17-7.mol
|
Ruxolitinib phosphate Eigenschaften
- Schmelzpunkt:
- 186-190°C
- storage temp.
- Refrigerator
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H301 |
Giftig bei Verschlucken. |
Akute Toxizität oral |
Kategorie 3 |
Achtung |
![GHS hazard pictograms]() src="/GHS06.jpg" width="20" height="20" /> |
P264, P270, P301+P310, P321, P330,P405, P501 |
| H361 |
Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. |
Reproduktionstoxizität |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
| H373 |
Kann die Organe schädigen bei längerer oder wiederholter Exposition. |
Spezifische Zielorgan-Toxizität (wiederholte Exposition) |
Kategorie 2 |
Warnung |
|
P260, P314, P501 |
|
| Sicherheit |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
|
Ruxolitinib phosphate Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
The phosphate salt of Ruxolitinib (R702000). Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.
Definition
ChEBI: A phosphate salt obtained by reaction ruxolitinib with one equivalent of phosphoric acid. Used for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essent
al thrombocythemia myelofibrosis.
Clinical Use
Ruxolitinib phosphate is a potent, selective, ATP competitive
inhibitor of tyrosine-protein kinases JAK1 and JAK2 which acts by
attenuating cytokine signaling and promotes apoptosis. Ruxolitinib
was discovered and developed by Incyte, is marketed under the
brand name Jakafi,and is approved for the treatment of patients
with myelofibrosis (MF), including primary MF, post-polycythemia
vera MP, and post-essential thrombocythemia MF. Ruxolitinib
is also undergoing clinical evaluation against a wide variety
of cancer indications including metastatic prostate cancer, pancreatic
cancer, multiple myeloma, leukemia, non-Hodgkin lymphoma, and breast cancer. Additionally, ruxolitinib is being evaluated for
the treatment of psoriasis and thrombocytopenia.
Ruxolitinib phosphate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Ruxolitinib phosphate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 300)Lieferanten
- (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate
- INCB 018424
- Ruxolitinib, Phosphate Salt
- Ruxolitinib, Phosphate
- (βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazole-1-propanenitrile Phosphate
- (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid
- Ruxolitinib (INCB-18424) phosphate
- Jakafi (ruxolitinib)
- Ruxolitinib phosphate, >=98%
- (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
- RUXOLITINIB(INCB018424) PHOSPHATE
- Ruxotinib phosphate
- Ruxolitinib phosphate(INCB018424)
- Beta-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(Betar)-1H-pyrazole-1-propanenitrile, phosphate
- (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosph
- INCB 018424(Ruxolitinib Phosphate)
- INCB 018424 (phosphate)
- INCB018424 (phosphate)
- INCB-018424 (phosphate)
- (R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate
- INCB018424;INCB-018424;INCB 018424
- INCB018424 PHOSPHATE;INCB 018424 PHOSPHATE;INCB-018424 PHOSPHATE;RUXOLITINIB
- RUXOLITINIB PHOSPHATE (INCB018424 PHOSPHATE)
- INC 424 phosphate
- Ruxolitinib phosphate ISO 9001：2015 REACH
- Ruxolitinib Phosphate (INC-424, INCB-18424, INCB-018424, Jakafi and Jakavi)
- phosphenoperoxoic acid compound with (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile and dihydrogen (1:1:1)
- (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate
- 10-dimethoxyptercarpan
- INC424
- IINCB018424 phosphate
- (βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate
- 1092939-17-7
- C17H18N6H3PO4
- C17H21N6O4P
- Intracellular signaling.
- Inhibitors
- Antineoplastic
- API
